Globus Medical (GMED) Sees Sequential Revenue Surge, Citizens JMP Maintains Market Perform Rating

Globus Medical Inc. (NYSE:GMED) ranks among the best mid-cap stocks with huge upside potential. Following the publication of Globus Medical Inc. (NYSE:GMED)’s second-quarter 2025 results, Citizens JMP reaffirmed its Market Perform rating on the company on August 20.

Globus Medical Inc. (NYSE:GMED) reported a total sales increase of 3% year-over-year, or 5% on a day-adjusted basis, slightly above analyst expectations. The company’s adjusted earnings per share came in at $0.86, exceeding Street projections of $0.75 by around 15%.

The medical device manufacturer reported that product supply “dramatically improved” throughout its business, and that operational issues that were mentioned in the first quarter had mostly dissipated. The results revealed a turnaround in Enabling Technologies revenue, which was down 4% year-over-year but surged nearly 60% sequentially after a 31% year-over-year drop in the first quarter of 2025.

Medical device manufacturer Globus Medical Inc. (NYSE:GMED) creates and markets healthcare solutions for musculoskeletal conditions both nationally and internationally.

While we acknowledge the potential of GMED as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.